Director/PDMR Shareholding

RNS Number : 4400G

Advanced Medical Solutions Grp PLC

12 May 2011

 



12 May 2011

Advanced Medical Solutions Group plc

("AMS" or the "Company")

Directors' shareholdings

Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, announces that the following Directors purchased ordinary shares of 5 pence each ("Ordinary Shares") on 11 May 2011, as part of the Deferred Share Bonus Plan.  These Ordinary Shares were bought at a price of 83 pence per share and, under the terms of the Plan, will be held in trust on their behalf.

Director	Shares purchased	Resultant holding	% of issued share capital
Chris Meredith, Chief Executive Officer	6641	1,132,376	0.7
Mary Tavener, Group Finance Director	5371	2,060,882	1.3

- Ends -

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc	Tel: [phone]
Chris Meredith, Chief Executive Officer Mary Tavener, Group Finance Director
Tavistock Communications	Tel: [phone]
John West / Chris Munden / Andrew Dunn / Lydia Eades
Investec Bank plc	Tel: [phone]
Gary Clarence / Daniel Adams / Patrick Robb

Notes to Editors:

AMS' advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foams. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids and provide an optimal environment for healing to occur. Silver is widely recognised as a safe and effective broad-spectrum anti-microbial agent for infection control.

AMS' wound closure and sealants products are based on cyanoacrylate adhesive ("superglue") technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites.

 

END

 

 

RDSBRGDUBUBBGBB